Stock 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
18 HKD +0.11% Intraday chart for SciClone Pharmaceuticals (Holdings) Limited 0.00% +29.31%
04-18 Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 MT
04-01 SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
MT
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
MT
Sciclone Pharmaceuticals Limited Announces Executive Changes
CI
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
MT
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
CI
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
CI
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%
MT
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
CI
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection
MT
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
CI
SciClone Commercially Launches Neuroblastoma Treatment in China
MT
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
CI
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
CI
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022
CI
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company
CI
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.
CI
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6600 Stock
  4. News SciClone Pharmaceuticals (Holdings) Limited